
Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses risk factors that oncology nurses should be aware of when thinking about chemotherapy-induced peripheral neuropathy (CIPN).

Darcy has over 30 years of experience as an oncology nurse serving in a variety of roles. She is currently the Survivorship Nurse Navigator at the Helen F Graham Cancer Center & Research Institute. In addition to her clinical experience, she has held leadership positions in the local and national Oncology Nursing Society and has authored articles, book chapters, and has presented locally and nationally on numerous oncology topics. Darcy is passionate about mentoring new oncology nurses and helping patients maximize their quality of life.

Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses risk factors that oncology nurses should be aware of when thinking about chemotherapy-induced peripheral neuropathy (CIPN).

Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses the role nurses play in treating patients with chemotherapy-induced peripheral neuropathy (CIPN).

There are over 14 million cancer survivors in the United States, a number that is expected to grow exponentially due to an aging population and improved methods for early detection and treatment. In the Institute of Medicine (IOM) report “From Cancer Patient to Cancer Survivor: Lost in Transition” the importance of addressing the ongoing physical and psychosocial challenges of cancer survivors was emphasized to encourage the multidisciplinary approach to survivorship as a distinct phase of the cancer continuum. Oncology nurses have an essential role in ensuring that quality survivorship care begins at diagnosis and continues throughout the balance of our patients' lives.

Published: February 16th 2016 | Updated:

Published: May 23rd 2016 | Updated:

Published: April 30th 2016 | Updated: